Pharma as an industry suffers from cerebral dysmorphia: the structure of its head does not always match its body. The industry is struggling to align its executive management layer with the diversity in its workforce. There are short-term, symptomatic fixes for the condition but curative therapy is a protracted process that, at current rates, will take until 2050 to complete.
Beth Crowley is now senior vice president and chief product development officer at Celldex Therapeutics Inc., a clinical-stage antibody...
